AcouSort AB (ACOU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AcouSort AB (ACOU) has a cash flow conversion efficiency ratio of -0.260x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.86 Million ≈ $-522.69K USD) by net assets (Skr18.65 Million ≈ $2.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AcouSort AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
AcouSort AB - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how AcouSort AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AcouSort AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AcouSort AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RS Public Company Limited
BK:RS
|
-0.051x |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
0.049x |
|
Alice QUEEN Ltd
AU:AQX
|
5.144x |
|
Metalsgrove Mining Ltd
AU:MGA
|
-0.095x |
|
Dynaciate Group Bhd
KLSE:5178
|
0.016x |
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
0.138x |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
-0.039x |
|
Viking Mines Ltd
AU:VKA
|
-0.290x |
Annual Cash Flow Conversion Efficiency for AcouSort AB (2013–2024)
The table below shows the annual cash flow conversion efficiency of AcouSort AB from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see ACOU market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr8.46 Million ≈ $910.75K |
Skr-18.81 Million ≈ $-2.02 Million |
-2.222x | -69.95% |
| 2023-12-31 | Skr24.14 Million ≈ $2.60 Million |
Skr-31.56 Million ≈ $-3.40 Million |
-1.308x | -763.33% |
| 2022-12-31 | Skr20.11 Million ≈ $2.16 Million |
Skr3.96 Million ≈ $426.70K |
0.197x | +159.62% |
| 2021-12-31 | Skr33.02 Million ≈ $3.55 Million |
Skr-10.92 Million ≈ $-1.17 Million |
-0.331x | +54.92% |
| 2020-12-31 | Skr9.59 Million ≈ $1.03 Million |
Skr-7.04 Million ≈ $-757.08K |
-0.733x | +55.87% |
| 2019-12-31 | Skr5.92 Million ≈ $637.30K |
Skr-9.84 Million ≈ $-1.06 Million |
-1.662x | -250.06% |
| 2018-12-31 | Skr15.58 Million ≈ $1.68 Million |
Skr-7.40 Million ≈ $-796.04K |
-0.475x | +78.37% |
| 2017-12-31 | Skr3.88 Million ≈ $417.87K |
Skr-8.53 Million ≈ $-917.43K |
-2.195x | -10113.03% |
| 2016-12-31 | Skr9.96 Million ≈ $1.07 Million |
Skr-214.00K ≈ $-23.03K |
-0.021x | +99.78% |
| 2015-12-31 | Skr78.63K ≈ $8.46K |
Skr-757.00K ≈ $-81.47K |
-9.627x | +57.84% |
| 2014-12-31 | Skr376.48K ≈ $40.52K |
Skr-8.60 Million ≈ $-925.17K |
-22.835x | -89.13% |
| 2013-12-31 | Skr249.47K ≈ $26.85K |
Skr-3.01 Million ≈ $-324.14K |
-12.074x | -- |
About AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC … Read more